Leerink Partners Rates Ionis Pharmaceuticals (IONS) buy

On June 25, 2026, Leerink Partners analyst Mani Foroohar reiterated a buy rating on Ionis Pharmaceuticals, Inc. (IONS) with a price target of $129.00. This target reflects a significant gap compared to where the stock has been trading recently, suggesting the firm sees plenty of room for the share price to climb.

Significant Upside in the Leerink Target

The gap between the current share price and the $129.00 target is the main story here. With Ionis trading at $81.18 on Thursday, Leerink's valuation implies the stock could gain roughly $47 per share if it reaches that goal. This bullish stance stands out even as other analysts have been more conservative. For instance, the average price target among 22 analysts sits at $83.82, which is only slightly above the current market price. Leerink’s target is also well above the high end of the 52-week trading range, which topped out at $86.74.

Ionis Stock Performance and Trends

Ionis shares have shown some strength recently, trading well above their 200-day moving average of $72.00. On Thursday, the stock was priced at $81.18, closer to its yearly high than its low of $44.20. Despite this upward trend, the company is not currently profitable, meaning it does not have a meaningful P/E ratio. Investors are paying a premium for the company's future potential in the biotech space, as shown by its high debt-to-equity ratio of 497.8 and its focus on long-term clinical development.

Recent Earnings Data

In its most recent financial reports, Ionis Pharmaceuticals reported revenue of $874.09 million. However, the company faced a revenue decline of 40.7% compared to the previous period. Earnings per share came in at -$3.48, and the company maintains a negative net margin of 64.6%. These figures are common for biotech firms that spend heavily on research and development before their drugs reach full commercial success. Investors can look for updated financial results when the company reports its next earnings on November 4, 2026.

Executive Leadership and Insider Buying

Several top executives at Ionis have been active in the market recently. On June 26, 2026, EVP Eugene Schneider bought 26,000 shares at an average price of $60.89, a transaction totaling about $1.58 million. On that same day, EVP Joseph Baroldi purchased 5,635 shares at $49.19 each, worth roughly $277,181. CEO Brett Monia also had activity on June 24, 2026, buying 14,565 shares at $32.60 for a total of $474,819, while also reporting a sale of the same number of shares that day. These purchases by high-level officers often suggest that those closest to the company's operations believe in its long-term direction.

Shifting Analyst Perspectives

While Leerink remains very bullish, other firms have adjusted their views lately. On October 15, 2026, UBS upgraded Ionis to a Buy rating and raised its target from $46.00 to $88.00. Earlier, on September 24, 2026, HC Wainwright & Co. reiterated its own Buy rating with a $100.00 target. Not everyone is as optimistic, however; on September 8, 2026, BMO Capital maintained a Market Perform rating with a $54.00 target, and Goldman Sachs held a Neutral rating with a $56.00 target. This wide range of targets, from $54 to $129, shows that Wall Street is divided on exactly how much the company's drug pipeline is worth.

RNA-Targeted Medicines

Ionis Pharmaceuticals is a California-based biotech company that specializes in RNA-targeted medicines. They have several products already on the market, including treatments for rare conditions like spinal muscular atrophy and hereditary transthyretin-mediated amyloidosis. Much of the company's value lies in its deep pipeline of drugs currently in Phase 3 clinical trials, which target cardiovascular diseases and rare neurological disorders. Because these medicines are still being tested or are in the early stages of sales, the company's stock price often moves based on clinical trial news and analyst expectations rather than current profits.

Looking Ahead for Ionis

With a major gap between the current stock price and Leerink's $129.00 target, the next few months will be important for Ionis. Investors will likely focus on the upcoming earnings report in November and any updates regarding their Phase 3 clinical trials. While insider buying from the CEO and EVPs suggests internal confidence, the wide variety of analyst price targets means the market is still weighing the risks of the company's high debt and current lack of profitability against its innovative medical pipeline.